Prothena Provides Updates on PRX012, PRX123, Birtamimab and

Updates on PRX012 and PRX123 for treatment of Alzheimer’s disease, and on birtamimab for treatment of AL amyloidosis



Remain on track with partnered programs: Bristol Myers Squibb , Roche and...

Related Keywords

Novo Nordisk , European Medicines Agency , Nasdaq , Global Neuroscience Research , Prothena Corporation , Drug Administration , Development Collaboration , Bristol Myers Squibb , Business Updates , Fast Track Designation , Bristol Myers , Myers Squibb , Mayo Stage , Orphan Drug Designation , European Medicines , Special Protocol Assessment , Financial Position , Markets ,